RAIN - RAIN Investors: Contact Robbins LLP for Information Regarding the Pending Lead Plaintiff Deadline in the Rain Oncology Inc. Securities Fraud Class Action | Benzinga
SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Rain Oncology Inc. (NASDAQ:RAIN) securities between July 20, 2021 and May 19, 2023. Rain Oncology is a late-stage precision oncology company that develops therapies that target oncogenic drivers to genetically select patients in the United States.
For more information, submit a form, email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
What is this Case About: Rain Oncology Inc. (RAIN) Misled Investors Regarding the Viability of its Lead Drug Candidate Milademetan
According to the complaint, Rain's lead drug candidate was milademetan, a drug designed to treat dedifferentiated liposarcoma ("DD LPS"). Rain first licensed milademetan from Daiichi Sankyo Company, Limited, in September 2020 based on positive results from a Phase 1 clinical trial. Instead of conducting additional trials to test the safety and dosing ...